Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, Research Committee of the Korean Liver Cancer Association
Clin Mol Hepatol 2023;29(3):521-541. Published online July 1, 2023
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
Citations
Citations to this article as recorded by
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer Yuqi Feng, Letian Fang, Guangwen Cao Hepatoma Research.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis” Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(1): e93. CrossRef
A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges Shuwei Zhou, Chenxin Song, Pei Liu, Shenghong Ju, Yuan-Cheng Wang European Journal of Radiology.2025; 186: 112057. CrossRef
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM Jiahao Li, Lei Xian, Xinsen Wang, Yingnan Liu, Jiarui Li Frontiers in Immunology.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A risk prediction model for nausea and vomiting after TACE: a cross-sectional study Yali Dai, Mengting Zeng, Hong He, Miao Cai BMC Gastroenterology.2025;[Epub] CrossRef
Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound Linda Galasso, Jacopo Iaccarino, Giorgio Esposto, Gabriele Giansanti, Irene Mignini, Raffaele Borriello, Gianpaolo Vidili, Antonio Gasbarrini, Maria Elena Ainora, Maria Assunta Zocco Diagnostics.2025; 15(11): 1380. CrossRef
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective In Joon Lee, Hyo-Cheol Kim Korean Journal of Radiology.2025; 26(7): 688. CrossRef
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991. CrossRef
Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial Yanting Zou, Szu‐Yuan Wu, Wanqin Zhang, Wei Zhang, Xizhong Shen, Xudong Qu, Qunyan Yao Liver International.2025;[Epub] CrossRef
Embolic efficacy and safety profile of UniPearls® microspheres for hepatic artery embolization in domestic pigs Junqing Xi, Kai Liu, Min Xu, Li Dai, Zhengqiang Yang, Baosheng Ren Journal of Materials Science: Materials in Medicine.2025;[Epub] CrossRef
Nomogram for predicting post-transarterial chemoembolization survival in recurrent patients with hepatitis B virus-associated hepatocellular carcinoma Zhang-you Guo, Mu-yang Tu, Yin-shan Yang, Ling-xiang Xu, Dan-dan Fan Scientific Reports.2025;[Epub] CrossRef
Reassessing the L. reuteri/ indole-3-lactic acid pathway in TACE-related liver injury Xiang Zhang, Hui gong, Datian Chen Journal of Hepatology.2025;[Epub] CrossRef
Targeting lactic acidosis in the tumor microenvironment: Enhancing TACE efficacy in hepatocellular carcinoma Shuyi Hao, Hong Yao, Haojie Yu, Lijun Wang, Tingdong Yu, Hongping Xia, Yong Zha Liver Research.2025; 9(4): 273. CrossRef
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li Life Sciences.2024; 342: 122540. CrossRef
Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization Xiaoliu Liang, Hui Liu, Hu Chen, Xuqi Peng, Zhenjie Li, Minglei Teng, Yisheng Peng, Jiwei Li, Linyu Ding, Jingsong Mao, Chengchao Chu, Hongwei Cheng, Gang Liu Aggregate.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) in liver cancer: a protocol for a randomised controlled trial Haiyan Chen, Hanxiao Lu, Huimin Zhou, Bo Wu, Zhixia Dong, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang BMJ Open.2024; 14(5): e083228. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022 Yuri Cho, Bo Hyun Kim, Young-Suk Lim Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis Huipeng Fang, Qiao Ke, Shiji Wu, Qiang Tu, Lei Wang Frontiers in Immunology.2024;[Epub] CrossRef
Dexamethasone and N-acetylcysteine before transarterial chemoembolization in hepatocellular carcinoma: A Western perspective Marco Biolato, Maurizio Pompili World Journal of Gastroenterology.2024; 30(31): 3635. CrossRef
Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy Feng Guo American Journal of Cancer Research.2024; 14(9): 4580. CrossRef
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma? Hyo-Cheol Kim Clinical and Molecular Hepatology.2023; 29(4): 984. CrossRef
Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion Dan Yang, Jiaojiao Du, Weijie Nie, Chaozhi Wang, Zhufang Ma Medicine.2023; 102(45): e35713. CrossRef
First
Prev
